FDA Accepts sBLA for UCB’s Bimzelx in Moderate-to-Severe HS and Additional 2mL Device Presentations
The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for bimekizumab-bkzx (Bimzelx, UCB), an interleukin(IL)-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). In addition, a second sBLA for the Bimzelx 2mL device presentations has also been accepted, according to UCB. “The most recent sBLA […]